Globenewswire·2026-03-23 01:38Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Soleno Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3] Group 1: Class Action Details - Investors who bought Soleno common stock between March 26, 2025, and November 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 5, 2026 [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4] - The firm has achieved notable settlements, including over $438 million in 2019, and has been consistently ranked among the top firms in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Soleno made false or misleading statements regarding the safety of its Phase 3 clinical trial program for diazoxide choline extended-release tablets (DCCR), particularly concerning safety risks related to fluid retention [5] - It is claimed that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to potential adverse events post-launch [5]